Failure of nasogastric omeprazole suspension in pediatric intensive care patients

To determine the efficacy of nasogastric administration of omeprazole suspension in raising the gastric pH >4 in critically ill pediatric patients and to determine the most appropriate dosing regimen for this indication. Open-label pharmacodynamic study. Twenty-six bed tertiary-care pediatric int...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric critical care medicine 2005-03, Vol.6 (2), p.182-187
Hauptverfasser: Haizlip, Julie A, Lugo, Ralph A, Cash, Jared J, Vernon, Donald D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 187
container_issue 2
container_start_page 182
container_title Pediatric critical care medicine
container_volume 6
creator Haizlip, Julie A
Lugo, Ralph A
Cash, Jared J
Vernon, Donald D
description To determine the efficacy of nasogastric administration of omeprazole suspension in raising the gastric pH >4 in critically ill pediatric patients and to determine the most appropriate dosing regimen for this indication. Open-label pharmacodynamic study. Twenty-six bed tertiary-care pediatric intensive care unit. Mechanically ventilated children aged 1-18 yrs with an additional risk factor for stress ulcer formation. Continuous gastric pH monitoring was performed during administration and dose titration of omeprazole suspension to achieve the goal of gastric pH >4 for greater than 75% of the dosing interval. Data were collected from 18 patients. Subjects were categorized based on the pharmacologic response to nasogastric administration of 1 mg/kg omeprazole suspension (maximum 20 mg) as rapid (n = 9), late (n = 5), and nonresponders (n = 4). Rapid responders required 0.72 mg/kg per day omeprazole suspension to achieve adequate gastric pH elevation for stress ulcer prophylaxis. Late responders required 1.58 mg/kg per day. Nonresponders did not achieve adequate elevation of gastric pH for stress ulcer prophylaxis. Nasogastric administration of omeprazole suspension has variable efficacy in critically ill pediatric patients. Half of the studied subjects either required significant dose titrations to achieve gastric acid suppression or did not respond to nasogastric administration of omeprazole suspension.
doi_str_mv 10.1097/01.PCC.0000154953.12594.9E
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67459012</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67459012</sourcerecordid><originalsourceid>FETCH-LOGICAL-c232t-70166fe731a7b9661d679bccb21625a57992a7ba693fd7dc963796a810b3a3593</originalsourceid><addsrcrecordid>eNpFkE1LxDAQhnNQ3HX1L0jx4K01H03ieJOyq8KCCnoOaZpKpG1q0gr66-3uFnYuAzPPOwMPQtcEZwSDvMUkey2KDE9FeA6cZYRyyDNYn6Al4RRSyRlfoPMYvyYERC7P0IJwybDAYoneNto1Y7CJr5NOR_-p4xCcSXxr-6D_fGOTOMbedtH5LnFd0tvK6T3iumE3_rGJ0dOBXg_OdkO8QKe1bqK9nPsKfWzW78VTun15fC4etqmhjA6pxESI2kpGtCxBCFIJCaUxJSWCcs0lAJ02WgCrK1kZEEyC0HcEl0wzDmyFbg53--C_RxsH1bpobNPozvoxKiFzDpjQCbw_gCb4GIOtVR9cq8OvIljtJCpM1CRRHSWqvUQF6yl8NX8Zy9ZWx-hskP0DbKpwoA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67459012</pqid></control><display><type>article</type><title>Failure of nasogastric omeprazole suspension in pediatric intensive care patients</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Haizlip, Julie A ; Lugo, Ralph A ; Cash, Jared J ; Vernon, Donald D</creator><creatorcontrib>Haizlip, Julie A ; Lugo, Ralph A ; Cash, Jared J ; Vernon, Donald D</creatorcontrib><description>To determine the efficacy of nasogastric administration of omeprazole suspension in raising the gastric pH &gt;4 in critically ill pediatric patients and to determine the most appropriate dosing regimen for this indication. Open-label pharmacodynamic study. Twenty-six bed tertiary-care pediatric intensive care unit. Mechanically ventilated children aged 1-18 yrs with an additional risk factor for stress ulcer formation. Continuous gastric pH monitoring was performed during administration and dose titration of omeprazole suspension to achieve the goal of gastric pH &gt;4 for greater than 75% of the dosing interval. Data were collected from 18 patients. Subjects were categorized based on the pharmacologic response to nasogastric administration of 1 mg/kg omeprazole suspension (maximum 20 mg) as rapid (n = 9), late (n = 5), and nonresponders (n = 4). Rapid responders required 0.72 mg/kg per day omeprazole suspension to achieve adequate gastric pH elevation for stress ulcer prophylaxis. Late responders required 1.58 mg/kg per day. Nonresponders did not achieve adequate elevation of gastric pH for stress ulcer prophylaxis. Nasogastric administration of omeprazole suspension has variable efficacy in critically ill pediatric patients. Half of the studied subjects either required significant dose titrations to achieve gastric acid suppression or did not respond to nasogastric administration of omeprazole suspension.</description><identifier>ISSN: 1529-7535</identifier><identifier>DOI: 10.1097/01.PCC.0000154953.12594.9E</identifier><identifier>PMID: 15730606</identifier><language>eng</language><publisher>United States</publisher><subject>Administration, Intranasal ; Adolescent ; Anti-Ulcer Agents - administration &amp; dosage ; Child ; Child, Preschool ; Critical Care ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Gastric Acidity Determination ; Humans ; Hydrogen-Ion Concentration - drug effects ; Infant ; Intubation, Gastrointestinal ; Male ; Omeprazole - administration &amp; dosage ; Respiration, Artificial ; Respiratory Insufficiency - physiopathology ; Respiratory Insufficiency - therapy ; Stomach - drug effects ; Stomach - physiopathology ; Treatment Failure</subject><ispartof>Pediatric critical care medicine, 2005-03, Vol.6 (2), p.182-187</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c232t-70166fe731a7b9661d679bccb21625a57992a7ba693fd7dc963796a810b3a3593</citedby><cites>FETCH-LOGICAL-c232t-70166fe731a7b9661d679bccb21625a57992a7ba693fd7dc963796a810b3a3593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15730606$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haizlip, Julie A</creatorcontrib><creatorcontrib>Lugo, Ralph A</creatorcontrib><creatorcontrib>Cash, Jared J</creatorcontrib><creatorcontrib>Vernon, Donald D</creatorcontrib><title>Failure of nasogastric omeprazole suspension in pediatric intensive care patients</title><title>Pediatric critical care medicine</title><addtitle>Pediatr Crit Care Med</addtitle><description>To determine the efficacy of nasogastric administration of omeprazole suspension in raising the gastric pH &gt;4 in critically ill pediatric patients and to determine the most appropriate dosing regimen for this indication. Open-label pharmacodynamic study. Twenty-six bed tertiary-care pediatric intensive care unit. Mechanically ventilated children aged 1-18 yrs with an additional risk factor for stress ulcer formation. Continuous gastric pH monitoring was performed during administration and dose titration of omeprazole suspension to achieve the goal of gastric pH &gt;4 for greater than 75% of the dosing interval. Data were collected from 18 patients. Subjects were categorized based on the pharmacologic response to nasogastric administration of 1 mg/kg omeprazole suspension (maximum 20 mg) as rapid (n = 9), late (n = 5), and nonresponders (n = 4). Rapid responders required 0.72 mg/kg per day omeprazole suspension to achieve adequate gastric pH elevation for stress ulcer prophylaxis. Late responders required 1.58 mg/kg per day. Nonresponders did not achieve adequate elevation of gastric pH for stress ulcer prophylaxis. Nasogastric administration of omeprazole suspension has variable efficacy in critically ill pediatric patients. Half of the studied subjects either required significant dose titrations to achieve gastric acid suppression or did not respond to nasogastric administration of omeprazole suspension.</description><subject>Administration, Intranasal</subject><subject>Adolescent</subject><subject>Anti-Ulcer Agents - administration &amp; dosage</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Critical Care</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Gastric Acidity Determination</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration - drug effects</subject><subject>Infant</subject><subject>Intubation, Gastrointestinal</subject><subject>Male</subject><subject>Omeprazole - administration &amp; dosage</subject><subject>Respiration, Artificial</subject><subject>Respiratory Insufficiency - physiopathology</subject><subject>Respiratory Insufficiency - therapy</subject><subject>Stomach - drug effects</subject><subject>Stomach - physiopathology</subject><subject>Treatment Failure</subject><issn>1529-7535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LxDAQhnNQ3HX1L0jx4K01H03ieJOyq8KCCnoOaZpKpG1q0gr66-3uFnYuAzPPOwMPQtcEZwSDvMUkey2KDE9FeA6cZYRyyDNYn6Al4RRSyRlfoPMYvyYERC7P0IJwybDAYoneNto1Y7CJr5NOR_-p4xCcSXxr-6D_fGOTOMbedtH5LnFd0tvK6T3iumE3_rGJ0dOBXg_OdkO8QKe1bqK9nPsKfWzW78VTun15fC4etqmhjA6pxESI2kpGtCxBCFIJCaUxJSWCcs0lAJ02WgCrK1kZEEyC0HcEl0wzDmyFbg53--C_RxsH1bpobNPozvoxKiFzDpjQCbw_gCb4GIOtVR9cq8OvIljtJCpM1CRRHSWqvUQF6yl8NX8Zy9ZWx-hskP0DbKpwoA</recordid><startdate>200503</startdate><enddate>200503</enddate><creator>Haizlip, Julie A</creator><creator>Lugo, Ralph A</creator><creator>Cash, Jared J</creator><creator>Vernon, Donald D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200503</creationdate><title>Failure of nasogastric omeprazole suspension in pediatric intensive care patients</title><author>Haizlip, Julie A ; Lugo, Ralph A ; Cash, Jared J ; Vernon, Donald D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c232t-70166fe731a7b9661d679bccb21625a57992a7ba693fd7dc963796a810b3a3593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Administration, Intranasal</topic><topic>Adolescent</topic><topic>Anti-Ulcer Agents - administration &amp; dosage</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Critical Care</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Gastric Acidity Determination</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration - drug effects</topic><topic>Infant</topic><topic>Intubation, Gastrointestinal</topic><topic>Male</topic><topic>Omeprazole - administration &amp; dosage</topic><topic>Respiration, Artificial</topic><topic>Respiratory Insufficiency - physiopathology</topic><topic>Respiratory Insufficiency - therapy</topic><topic>Stomach - drug effects</topic><topic>Stomach - physiopathology</topic><topic>Treatment Failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haizlip, Julie A</creatorcontrib><creatorcontrib>Lugo, Ralph A</creatorcontrib><creatorcontrib>Cash, Jared J</creatorcontrib><creatorcontrib>Vernon, Donald D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haizlip, Julie A</au><au>Lugo, Ralph A</au><au>Cash, Jared J</au><au>Vernon, Donald D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Failure of nasogastric omeprazole suspension in pediatric intensive care patients</atitle><jtitle>Pediatric critical care medicine</jtitle><addtitle>Pediatr Crit Care Med</addtitle><date>2005-03</date><risdate>2005</risdate><volume>6</volume><issue>2</issue><spage>182</spage><epage>187</epage><pages>182-187</pages><issn>1529-7535</issn><abstract>To determine the efficacy of nasogastric administration of omeprazole suspension in raising the gastric pH &gt;4 in critically ill pediatric patients and to determine the most appropriate dosing regimen for this indication. Open-label pharmacodynamic study. Twenty-six bed tertiary-care pediatric intensive care unit. Mechanically ventilated children aged 1-18 yrs with an additional risk factor for stress ulcer formation. Continuous gastric pH monitoring was performed during administration and dose titration of omeprazole suspension to achieve the goal of gastric pH &gt;4 for greater than 75% of the dosing interval. Data were collected from 18 patients. Subjects were categorized based on the pharmacologic response to nasogastric administration of 1 mg/kg omeprazole suspension (maximum 20 mg) as rapid (n = 9), late (n = 5), and nonresponders (n = 4). Rapid responders required 0.72 mg/kg per day omeprazole suspension to achieve adequate gastric pH elevation for stress ulcer prophylaxis. Late responders required 1.58 mg/kg per day. Nonresponders did not achieve adequate elevation of gastric pH for stress ulcer prophylaxis. Nasogastric administration of omeprazole suspension has variable efficacy in critically ill pediatric patients. Half of the studied subjects either required significant dose titrations to achieve gastric acid suppression or did not respond to nasogastric administration of omeprazole suspension.</abstract><cop>United States</cop><pmid>15730606</pmid><doi>10.1097/01.PCC.0000154953.12594.9E</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1529-7535
ispartof Pediatric critical care medicine, 2005-03, Vol.6 (2), p.182-187
issn 1529-7535
language eng
recordid cdi_proquest_miscellaneous_67459012
source MEDLINE; Journals@Ovid Complete
subjects Administration, Intranasal
Adolescent
Anti-Ulcer Agents - administration & dosage
Child
Child, Preschool
Critical Care
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Gastric Acidity Determination
Humans
Hydrogen-Ion Concentration - drug effects
Infant
Intubation, Gastrointestinal
Male
Omeprazole - administration & dosage
Respiration, Artificial
Respiratory Insufficiency - physiopathology
Respiratory Insufficiency - therapy
Stomach - drug effects
Stomach - physiopathology
Treatment Failure
title Failure of nasogastric omeprazole suspension in pediatric intensive care patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T08%3A45%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Failure%20of%20nasogastric%20omeprazole%20suspension%20in%20pediatric%20intensive%20care%20patients&rft.jtitle=Pediatric%20critical%20care%20medicine&rft.au=Haizlip,%20Julie%20A&rft.date=2005-03&rft.volume=6&rft.issue=2&rft.spage=182&rft.epage=187&rft.pages=182-187&rft.issn=1529-7535&rft_id=info:doi/10.1097/01.PCC.0000154953.12594.9E&rft_dat=%3Cproquest_cross%3E67459012%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67459012&rft_id=info:pmid/15730606&rfr_iscdi=true